Incyte Corporation (INCY)

Incyte's stock has risen by 31.4% in the past six months and 38.42% over the past year. Key events impacting the stock price include the Q3 2025 earnings report, which exceeded analysts' expectations with an EPS of $2.26 and total revenues of $1.37 billion. Positive clinical trial results were announced for tafasitamab as a first-line treatment for diffuse large B-cell lymphoma, and the EMA's Committee recommended approval of Zynyz for advanced squamous cell carcinoma of the anal canal. Incyte Japan also announced the approval of Minjuvi for relapsed or refractory follicular lymphoma and Zynyz for the first-line treatment of advanced anal cancer. Several analysts have updated their ratings and price targets for Incyte, and the Q4 2025 earnings are expected to be released on February 10, 2026, with analysts projecting an EPS of $1.83.

Specific detailed information on the demand seasonality for Incyte Corp.'s products is not readily available in public search results. However, general trends indicate robust and increasing demand for its key products, such as Jakafi and Opzelura. Given that Incyte's products primarily address chronic or serious medical conditions, demand is likely driven by ongoing patient needs rather than significant seasonal fluctuations.

Incyte Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics within the biotechnology sector and the broader healthcare industry. The company's core mission is to address unmet medical needs, particularly in oncology, inflammation, and autoimmunity. Its major marketed products include Jakafi for myelofibrosis, polycythemia vera, and graft-versus-host disease; Monjuvi/Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; Iclusig for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; Zynyz for metastatic or recurrent locally advanced Merkel cell carcinoma; NIKTIMVO for chronic graft-versus-host disease; and Opzelura cream for atopic dermatitis and nonsegmental vitiligo. Incyte also has a pipeline of clinical-stage products, including treatments for ovarian cancer, other cancers, solid tumors, hidradenitis suppurativa (HS), nonsegmental vitiligo, prurigo nodularis, asthma, chronic spontaneous urticaria, systemic immune and neuro-immune disorders, and fibrodysplasia ossificans progressive.

Incyte is a multinational pharmaceutical company headquartered in Wilmington, Delaware, U.S. The company conducts discovery, development, and commercialization activities across multiple regions, including the United States, Europe, Canada, and Japan. It operates manufacturing and R&D locations in North America, Europe, and Asia. In May 2024, Incyte announced an expansion of its Delaware footprint with the acquisition of two new buildings in downtown Wilmington to consolidate U.S.-based teams and support future growth.

Incyte generally prioritizes transparency in its communication with investors and the public. However, the company has faced some legal issues in the past, including a lawsuit in 2018 regarding trade secret theft and a lawsuit in 2024 concerning COVID-19 vaccine mandates. A preclinical toxicology discovery from INCB000262, an asset acquired through the buyout of Escient Pharmaceuticals, led to the clinical development of the MRGPRX2 inhibitor being put on hold in November 2025.

Incyte Corporation has significant institutional ownership, with 1320 institutional owners and shareholders holding a total of 228,684,861 shares. Major institutional owners include Baker Bros. Advisors Lp, Baker Brothers Life Sciences, L.P., The Vanguard Group, Inc., BlackRock, Inc., Dodge & Cox, State Street Global Advisors, Inc., AQR Capital Management, LLC, Renaissance Technologies LLC, Geode Capital Management, LLC, and LSV Asset Management. A portion of the shares is also held by individual investors and company insiders, such as executives and board members.